S100A4 and cancer: To our knowledge, this study is the first to demonstrate the role of tumor-derived S100A4 in metastasis-associated osteoclastogenesis and the first to project the concept of blocking S100A4 as an effective strategy in the treatment of cancer-induced bone destruction.